Core Insights - BioNTech will present data from its oncology pipeline at the AACR Annual Meeting, highlighting advancements in mRNA cancer immunotherapies, immunomodulators, and targeted therapies [1][4] - The company aims to establish a future standard of care for advanced cancers through combination therapies that enhance anti-tumor activity [2] Oncology Pipeline Overview - BioNTech has a diversified oncology portfolio that includes over 20 active Phase 2 and Phase 3 clinical trials, focusing on mRNA cancer immunotherapies and the next-generation immunomodulator BNT327 [4] - The company is progressing towards becoming a multi-product oncology company with multiple data readouts expected in 2025 and 2026 [4] Key Presentations at AACR 2025 - Preclinical data for BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, will be presented, showing superior anti-tumor activity compared to single treatments [7] - Early clinical data from the Phase 1/2 trial of BNT327 in combination with TROP2-targeting ADC BNT325/DB-1305 will be shared, including safety and efficacy results [7] - Data from the Phase 1 trial of mRNA cancer immunotherapy candidate BNT116 in combination with anti-PD1 cemiplimab will be presented, focusing on frail patients with advanced non-small cell lung cancer [7] Collaboration and Development - BioNTech collaborates with Duality Biologics for the development of ADCs and has established partnerships with various pharmaceutical companies to enhance its oncology pipeline [9][15]